As of 2024-07-27, the EV/EBITDA ratio of Esperion Therapeutics Inc (ESPR) is -14.73. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ESPR's latest enterprise value is 495.81 mil USD. ESPR's TTM EBITDA according to its financial statements is -33.66 mil USD. Dividing these 2 quantities gives us the above ESPR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 9.3x | 7.8x |
| Forward P/E multiples | 5.4x - 12.1x | 9.4x |
| Fair Price | (1.53) - (1.84) | (1.72) |
| Upside | -162.8% - -175.5% | -170.7% |
| Date | EV/EBITDA |
| 2024-07-26 | -14.73 |
| 2024-07-25 | -14.73 |
| 2024-07-24 | -14.22 |
| 2024-07-23 | -14.22 |
| 2024-07-22 | -14.62 |
| 2024-07-19 | -14.51 |
| 2024-07-18 | -14.84 |
| 2024-07-17 | -15.80 |
| 2024-07-16 | -16.42 |
| 2024-07-15 | -15.13 |
| 2024-07-12 | -15.18 |
| 2024-07-11 | -15.07 |
| 2024-07-10 | -14.34 |
| 2024-07-09 | -14.96 |
| 2024-07-08 | -14.56 |
| 2024-07-05 | -14.84 |
| 2024-07-03 | -14.34 |
| 2024-07-02 | -14.22 |
| 2024-07-01 | -14.22 |
| 2024-06-28 | -13.55 |
| 2024-06-27 | -14.06 |
| 2024-06-26 | -13.32 |
| 2024-06-25 | -12.82 |
| 2024-06-24 | -13.32 |
| 2024-06-21 | -13.49 |
| 2024-06-20 | -13.94 |
| 2024-06-18 | -16.36 |
| 2024-06-17 | -17.21 |
| 2024-06-14 | -17.88 |
| 2024-06-13 | -17.43 |
| 2024-06-12 | -17.32 |
| 2024-06-11 | -17.38 |
| 2024-06-10 | -17.43 |
| 2024-06-07 | -16.81 |
| 2024-06-06 | -14.96 |
| 2024-06-05 | -14.17 |
| 2024-06-04 | -13.72 |
| 2024-06-03 | -13.66 |
| 2024-05-31 | -13.21 |
| 2024-05-30 | -13.94 |
| 2024-05-29 | -13.27 |
| 2024-05-28 | -12.87 |
| 2024-05-24 | -13.04 |
| 2024-05-23 | -13.72 |
| 2024-05-22 | -14.45 |
| 2024-05-21 | -14.62 |
| 2024-05-20 | -15.01 |
| 2024-05-17 | -14.34 |
| 2024-05-16 | -15.63 |
| 2024-05-15 | -14.00 |